1. Home
  2. SG vs ABUS Comparison

SG vs ABUS Comparison

Compare SG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$5.26

Market Cap

820.3M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.15

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
ABUS
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
820.3M
888.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SG
ABUS
Price
$5.26
$4.15
Analyst Decision
Hold
Strong Buy
Analyst Count
15
1
Target Price
$13.54
$5.00
AVG Volume (30 Days)
4.1M
2.0M
Earning Date
02-26-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$685,184,000.00
$14,606,000.00
Revenue This Year
$4.08
$125.30
Revenue Next Year
$10.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.43
116.64
52 Week Low
$5.14
$2.71
52 Week High
$30.12
$5.10

Technical Indicators

Market Signals
Indicator
SG
ABUS
Relative Strength Index (RSI) 31.44 47.87
Support Level $5.83 $3.62
Resistance Level $6.59 $4.26
Average True Range (ATR) 0.41 0.28
MACD -0.13 0.01
Stochastic Oscillator 5.93 59.55

Price Performance

Historical Comparison
SG
ABUS

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: